JP2013511975A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511975A5 JP2013511975A5 JP2012540503A JP2012540503A JP2013511975A5 JP 2013511975 A5 JP2013511975 A5 JP 2013511975A5 JP 2012540503 A JP2012540503 A JP 2012540503A JP 2012540503 A JP2012540503 A JP 2012540503A JP 2013511975 A5 JP2013511975 A5 JP 2013511975A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- disease virus
- newcastle disease
- virus clone
- clone according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28315409P | 2009-11-30 | 2009-11-30 | |
| EP09075536A EP2327764B1 (en) | 2009-11-30 | 2009-11-30 | New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
| EP09075536.4 | 2009-11-30 | ||
| US61/283,154 | 2009-11-30 | ||
| PCT/IB2010/002227 WO2011064630A1 (en) | 2009-11-30 | 2010-08-13 | New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013511975A JP2013511975A (ja) | 2013-04-11 |
| JP2013511975A5 true JP2013511975A5 (https=) | 2013-10-03 |
| JP5807788B2 JP5807788B2 (ja) | 2015-11-10 |
Family
ID=41581942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540503A Expired - Fee Related JP5807788B2 (ja) | 2009-11-30 | 2010-08-13 | ニューカッスル病ウイルスの新規クローン、その作製及び癌治療への応用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8377450B2 (https=) |
| EP (2) | EP2327764B1 (https=) |
| JP (1) | JP5807788B2 (https=) |
| KR (1) | KR20120106741A (https=) |
| CN (1) | CN102803477B (https=) |
| AT (1) | ATE539148T1 (https=) |
| CA (1) | CA2782189C (https=) |
| DK (1) | DK2327764T3 (https=) |
| ES (1) | ES2380289T3 (https=) |
| IL (1) | IL207623A (https=) |
| WO (1) | WO2011064630A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2380289T3 (es) * | 2009-11-30 | 2012-05-10 | United Cancer Research Institute | Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer |
| KR101653401B1 (ko) * | 2013-08-28 | 2016-09-12 | 주식회사 바이오포아 | 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄ |
| KR101636683B1 (ko) * | 2013-08-28 | 2016-07-07 | 주식회사 바이오포아 | 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄｍ |
| CA2967336C (en) * | 2014-11-07 | 2023-09-26 | Case Western Reserve University | Cancer immunotherapy using virus particles |
| RU2644676C1 (ru) * | 2016-10-18 | 2018-02-13 | Общество с ограниченной ответственностью "Витагор" (ООО "ВИТАГОР") | Штамм вируса болезни Ньюкасла NDVH-2 для изучения возможности разработки на его основе вирусного онколитического препарата |
| KR101964610B1 (ko) * | 2017-03-13 | 2019-04-03 | 대한민국 | 신규한 종양용해성 바이러스 및 이의 용도 |
| EP3552608A1 (en) * | 2018-04-09 | 2019-10-16 | Rapo Yerape B.H. Ltd | Increased activity of oncoloytic newcastle disease virus |
| EP3844268A1 (en) * | 2018-08-31 | 2021-07-07 | Thaller, Arno | Novel recombinant newcastle disease virus |
| CN113913553B (zh) * | 2021-10-15 | 2024-08-27 | 广西壮族自治区兽医研究所 | 基因ⅻ型新城疫病毒荧光定量rt-pcr检测试剂盒及其引物对 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU197846B (en) | 1984-07-02 | 1989-06-28 | Laszlo Csatary | Process for producing therapeutic composition suitable for treating virus infections |
| HU197517B (en) | 1984-07-30 | 1989-04-28 | Laszlo Csatary | Process for production of terapeutical composition applicable against virus infection |
| DE3806565A1 (de) | 1988-03-01 | 1989-09-14 | Deutsches Krebsforsch | Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen |
| US5124148A (en) | 1988-04-27 | 1992-06-23 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
| US5215745A (en) | 1988-04-27 | 1993-06-01 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
| HU203983B (en) | 1988-12-05 | 1991-11-28 | Mta Allatorvostudomanyi Kutato | Process for producing living vaccine against fowlpox |
| US5602023A (en) | 1992-03-24 | 1997-02-11 | Csatary; Laszlo K. | Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same |
| CA2132328C (en) | 1992-03-24 | 2000-10-31 | Laszlo K. Csatary | Vaccine containing live virus for therapy of viral diseases and malignancies |
| FR2701580B1 (fr) | 1993-02-10 | 1995-03-24 | Bull Sa | Procédé d'administration d'applications avec des protocoles standards. |
| EP2009119A1 (en) | 1993-04-30 | 2008-12-31 | Wellstat Biologics Corporation | Compositions for treating cancer using viruses |
| JPH08116976A (ja) | 1994-10-20 | 1996-05-14 | Chemo Sero Therapeut Res Inst | 免疫用核酸調製物およびこれを用いた免疫方法 |
| EP0770397B1 (en) | 1995-10-18 | 2004-04-21 | Akzo Nobel N.V. | Newcastle disease virus combination vaccine |
| FR2750866B1 (fr) | 1996-06-27 | 1998-11-27 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
| IL135507A0 (en) | 1997-10-09 | 2001-05-20 | Pro Virus Inc | Treatment of neoplasms with viruses |
| EP0974660A1 (en) | 1998-06-19 | 2000-01-26 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
| JP2003530301A (ja) | 1999-04-15 | 2003-10-14 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いた新生物の処置 |
| US7244558B1 (en) | 1999-05-05 | 2007-07-17 | University Of Maryland | Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines |
| WO2000077218A1 (en) | 1999-06-10 | 2000-12-21 | Agricultural Research Council | Vaccine for newcastle disease virus |
| HK1052950B (en) | 2000-06-26 | 2005-06-24 | Wellstat Biologics Corporation | Purging of cells using viruses |
| AU2001270164A1 (en) | 2000-06-26 | 2002-01-08 | The United States Of America As Represented By The Secretary Of Agriculture | Production of vaccines using transgenic plants |
| ES2278810T3 (es) | 2000-11-02 | 2007-08-16 | Intervet International Bv | Nucleoproteina recombinante mutante del virus de la enfermedad de newcastle (ndv) como marcador de vacuna. |
| IL145397A0 (en) | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
| WO2005113013A2 (en) | 2004-05-20 | 2005-12-01 | Theravir Management L.P. | Compositions of ndv and methods of use thereof for treatment of cancer |
| NZ537255A (en) | 2002-06-21 | 2009-04-30 | Wellstat Biologics Corp | Administration of therapeutic viruses |
| WO2004018025A1 (en) * | 2002-08-23 | 2004-03-04 | Schering Corporation | Pharmaceutical compositions |
| AU2003287472A1 (en) | 2002-11-05 | 2004-06-03 | Wellstat Biologics Corporation | Treating carcinoid neoplasms with therapeuthic viruses |
| US20060099189A1 (en) | 2003-03-24 | 2006-05-11 | Lorence Robert M | Anti-cancer virus desensitization method |
| US20070077559A1 (en) | 2003-03-24 | 2007-04-05 | Bamat Michael K | Newcastle disease virus administration |
| WO2005051330A2 (en) | 2003-11-25 | 2005-06-09 | United Cancer Research Institute | METHOD FOR TREATING HUMAN TUMOR CELLS WITH A NEWCASTLE DISEASE VIRUS STRAIN HAVING A p53 INDEPENDENT ONCOLYTIC EFFECT |
| US20060018884A1 (en) * | 2003-11-25 | 2006-01-26 | United Cancer Research Institute | Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent |
| NZ550430A (en) | 2004-04-27 | 2009-06-26 | Wellstat Biologics Corp | Cancer treatment using viruses and camptothecins |
| BRPI0517834A (pt) | 2004-11-12 | 2008-10-21 | Bayer Schering Pharma Ag | vìrus da doença de newcastle recombinante |
| ATE540698T1 (de) | 2005-07-14 | 2012-01-15 | Wellstat Biologics Corp | Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen |
| CN1772886A (zh) | 2005-09-02 | 2006-05-17 | 中国农业科学院哈尔滨兽医研究所 | 表达传染性法氏囊病毒VP2基因的重组新城疫LaSota弱毒疫苗株 |
| KR101492643B1 (ko) | 2005-12-02 | 2015-02-12 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도 |
| KR100801180B1 (ko) | 2006-09-26 | 2008-02-05 | 주식회사 고려비엔피 | 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신 |
| EP2091972B1 (en) | 2006-11-27 | 2016-01-13 | Schirrmacher, Dr., Volker | Multi-modal cancer therapy using viral hitch-hiking |
| WO2008140621A2 (en) * | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
| CN101205544B (zh) * | 2007-08-07 | 2010-12-08 | 中国人民解放军第四军医大学 | 肿瘤靶向性重组新城疫病毒及其构建方法 |
| ES2380289T3 (es) * | 2009-11-30 | 2012-05-10 | United Cancer Research Institute | Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer |
-
2009
- 2009-11-30 ES ES09075536T patent/ES2380289T3/es active Active
- 2009-11-30 EP EP09075536A patent/EP2327764B1/en active Active
- 2009-11-30 AT AT09075536T patent/ATE539148T1/de active
- 2009-11-30 DK DK09075536.4T patent/DK2327764T3/da active
-
2010
- 2010-08-13 CN CN201080054157.2A patent/CN102803477B/zh not_active Expired - Fee Related
- 2010-08-13 US US12/806,494 patent/US8377450B2/en not_active Expired - Fee Related
- 2010-08-13 EP EP10768541A patent/EP2507366A1/en not_active Withdrawn
- 2010-08-13 KR KR1020127013900A patent/KR20120106741A/ko not_active Ceased
- 2010-08-13 CA CA2782189A patent/CA2782189C/en active Active
- 2010-08-13 WO PCT/IB2010/002227 patent/WO2011064630A1/en not_active Ceased
- 2010-08-13 JP JP2012540503A patent/JP5807788B2/ja not_active Expired - Fee Related
- 2010-08-15 IL IL207623A patent/IL207623A/en active IP Right Grant
-
2013
- 2013-01-14 US US13/741,024 patent/US20140030229A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013511975A5 (https=) | ||
| AU2014204386B2 (en) | Method for treating tumor by using recombinant interferon with changed spatial configuration | |
| JP2015517511A5 (https=) | ||
| JP7239910B2 (ja) | 治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用 | |
| EP4186519A1 (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
| EP1551444B1 (en) | Method for treatment of demyelinating central nervous system disease using gm-csf | |
| WO2017177908A1 (zh) | Pd-l1和pd-l2重组蛋白及其用途 | |
| JP2017533192A (ja) | ペグ化インターフェロンのための投薬計画 | |
| Indrová et al. | Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I− tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines | |
| CN115804853A (zh) | 包含rna分子的组合物及其在制备瘤内注射剂中的用途 | |
| EP4282426A1 (en) | Method and pharmaceutical combination for preventing cancer recurrence | |
| EP4282427A1 (en) | Interferon-based cancer treatment method, and pharmaceutical combination | |
| CA2501701A1 (en) | Chemotherapeutic agent-incorporated pharmaceutical preparation | |
| JP7412576B2 (ja) | 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用 | |
| CN109966275A (zh) | 醌式查尔酮化合物在制备抗肿瘤药物中的应用 | |
| CN112843092A (zh) | 免疫细胞在治疗疾病中的应用及其制备方法 | |
| JP2022522914A (ja) | 医学的使用 | |
| JP2022522914A5 (https=) | ||
| Yang et al. | Increased Anti-tumor Effect by a Combination of HSV Thymidine Kinase Suicide Gene Therapy and Interferon-γ/GM-CSF Cytokine Gene Therapy in CT26 Tumor Model | |
| Ellis et al. | Human vaccines & immunotherapeutics: News November 2022 | |
| Ren et al. | EPEN-09. TARGETING EPHB2/ABL1 RESTORES ANTI-TUMOR IMMUNITY IN A PRECLINICAL MODEL OF EPENDYMOMA | |
| Lourdusamy et al. | EPEN-08. MULTI-OMICS PROFILES REVEAL UNIQUE DEFINING MOLECULAR FEATURES OF POSTERIOR FOSSA EPENDYMOMA SUBTYPE A FROM INFANTS | |
| Yılmaz | Oncolytic Virotherapy and The Immune System. | |
| HK40102291A (en) | Interferon-based cancer treatment method, and pharmaceutical combination | |
| Chang et al. | 632. Sustained Function and Enhanced Replicative Capacity of Anti-Tumor CD4+ Effectors by Enforced Co-Stimulation |